Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites

Molecular Immunology

Volumn 38, Issue 6, 2001, Pages 433-442

  Tsuji, Moriya ^a   Zavala, Fidel ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibodies; Liver stages; Malaria; Sporozoite; Synthetic peptides; T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL PROTEIN; CIRCUMSPOROZOITE PROTEIN; EPITOPE; EXPORTED PROTEIN 1; FREUND ADJUVANT; GAMMA INTERFERON; HEPATOCYTE ERYTHROCYTE PROTEIN 17; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; LIVER ANTIGEN; LIVER PROTEIN; LIVER STAGE ANTIGEN 3; MALARIA VACCINE; MEMBRANE PROTEIN; MULTIPLE ANTIGEN PEPTIDE; PEPTIDE; PHOSPHORYL LIPID A; POLYMER; POLYOXIME; PROTEIN SUBUNIT; QS 21; SPOROZOITE SURFACE PROTEIN 2; SYNTHETIC PEPTIDE; TETANUS TOXOID; THROMBOSPONDIN RELATED ANONYMOUS PROTEIN; UNCLASSIFIED DRUG;

ANOPHELES; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; B LYMPHOCYTE; CHEMICAL ENGINEERING; ERYTHROCYTE; FEASIBILITY STUDY; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPOROZOITE; T LYMPHOCYTE; VACCINATION; VACCINE PRODUCTION;

ANIMALS; ANTIGENS, PROTOZOAN; EPITOPES, T-LYMPHOCYTE; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

ANIMALIA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX;

EID: 0035652273     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(01)00079-7     Document Type: Review

References (80)

1. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization
2. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees
3. Localization of HLA-A2.1-restricted T-cell epitopes in the circumsporozoite protein of Plasmodium falciparum
4. Binding of malaria T-cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: Identification of a universal T-cell epitope in the Plasmodium falciparum circumsporozoite protein
5. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites
6. Immunogenic properties of multiple antigen peptide systems containing defined T- and B-epitopes
7. Plasmodium yoelii: 17 kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody
8. CD4(+) T-cell- and γ interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17 kDa hepatocyte erythrocyte protein
9. Immunization of man against P. falciparum and P. vivax malaria by use of attenuated sporozoites
10. Specificity of protection of man immunized against sporozoite-induced P. falciparum malaria
11. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver stage antigen 3
12. Identification and characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1
13. Extracellular processing and presentation of a 69-mer synthetic polypetide to MHC class I-restricted T-cells
14. Efficacy of murine malaria sporozoite vaccines: Implications for human vaccine development
15. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites
16. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum
17. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides
18. Presentation of T-cell epitopes assembled as multiple-antigen peptides to murine and human T lymphocytes
19. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites
20. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes
21. Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys
22. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
23. Successful immunization of humans with irradiated malaria sporozoites: Humoral and cellular responses of the protected individuals
24. Comparison of adjuvant formulations for cytotoxic T-cell induction using synthetic peptides
25. Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2
26. In vivo testing of subunit vaccines against malaria sporozoites using a rodent system
27. Potent induction of focused Th1-type cellular and humoral immune responses by RTS, S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine
28. Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants
29. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies
30. Linear and multiple antigen peptides containing defined T- and B-epitopes of the Plasmodium yoelii circumsporozoite protein: Antibody-mediated protection and boosting by sporozoite infection
31. Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes
32. Malaria vaccine: Immunization of mice with a synthetic T-cell helper epitope alone leads to protective immunity
33. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice
34. Preclinical evaluation of a synthetic Plasmodium falciparum MAP vaccine in Aotus monkeys and mice
35. Immunogenicity of multiple antigen peptides (MAP) containing T- and B-cell epitopes of the repeat region of the P. falciparum circumsporozoite protein
36. Acquired immunity to sporozoites
37. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax
38. Plasmodium falciparum polyoximes: Highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein
39. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccines of defined HLA genotypes
40. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B-cell and universal T-cell epitopes elicits immune responses in volunteers of diverse HLA types
41. Synthetic peptides entrapped in microparticles can elicit cytotoxic T-cell activity
42. Rationale for the development of engineered sporozoite malaria vaccine
43. Specificity of protective immunity produced by X-irradiated Plasmodium berghei sporozoites
44. Immunogenicity of Ty-VLP bearing a CD8+ T-cell epitope of the CS protein of P. yoelii: Enhanced memory response by boosting with recombinant vaccinia virus
45. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection
46. Re-investigation of the circumsporozoite protein-based induction of sterile immunity against Plasmodium berghei infection
47. CD8+ T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: Evidence that localization of peptide-specific CTLs is crucial for protection against malaria
48. Effector functions of circumsporozoite peptide-primed CD4+ T-cell clones against Plasmodium yoelii liver stages
49. A highly conserved amino acid sequence in thrombospondin, properdin and proteins from sporozoites and blood stages of a human malaria parasite
50. CD8+ cytolytic T-cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria
51. The relative contribution of antibodies, CD4+ and CD8+ T-cells to sporozoite-induced protection against malaria
52. Characterization of Plasmodium falciparum sporozoite surface protein 2
53. The synthetic, oxidized C-terminal fragment of the Plasmodium berghei circumsporozoite protein elicits a high protective response
54. Antigenic analysis of the repeat domain of the circumsporozoite protein of Plasmodium vivax
55. Multiple T helper cell epitopes of the circumsporozoite protein of Plasmodium berghei
56. Cloned cytotoxic T-cells recognize an epitope in the circumsporozoite protein and protect against malaria
57. Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response. Evidence that two peptide residues are buried in the MHC molecule
58. Analysis of the human antibody response to thrombospondin-related anonymous protein of Plasmodium falciparum
59. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T-cells
60. Gamma interferon, CD8+ T-cells and antibodies required for immunity to malaria sporozoites
61. Anopheles stephensi salivary glands bear receptors for region I of the circumsporozoite protein of Plasmodium falciparum
62. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules
63. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria
64. TRAP is necessary for gliding motility and infectivity of Plasmodium sporozoites
65. Plasmodium yoelii: Peptide immunization induces protective CD4+ T-cells against a previously unrecognized cryptic epitope of the circumsporozoite protein
66. Incorporation of T- and B-epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria
67. CD4+ cytolytic T-cell clone confers protection against murine malaria
68. Use of human universally antigenic tetanus toxin T-cell epitopes as carriers for human vaccination
69. Induction of a cytotoxic T-cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): Further enhancement by pre-injection of IFA alone
70. Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway
71. Induction of protective polyclonal antibodies by immunization with a Plamodium yoelii circumsporozoite protein multiple antigen peptide vaccine
72. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T-cell- and IFN-γ-dependent elimination of infected hepatocytes
73. CD8+ T-cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites
74. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides
75. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin
76. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasites
77. Protective anti-sporozoite antibodies induced by a chemically defined synthetic vaccine
78. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes
79. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria
80. Synthetic peptide vaccine confers protection against murine malaria